PARIS, April 7 (Reuters) – Sanofi and Regeneron announced on Thursday that the European Commission has extended marketing authorization for their treatment Dupixent to treat severe asthma with type 2 inflammatory signature in children aged six to Eleven years.
(Written by Nicolas Delame and Myriam Rivet)